Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 4/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.41 |
| ▸ | CACNB2 | Q08289 | 1/20 | 0.41 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL77244 | 1.00 | TSHR (0.58) | TSHRLMNAMAPK1CACNA2D1CACNB2 | |
| SCHEMBL235417 | 1.00 | TSHR (0.58) | TSHRLMNAMAPK1CACNA2D1CACNB2 | |
| Carbamic Acid SCHEMBL10434705 | 0.89 | TSHR (0.48) | TSHRLMNAMAPK1CYP2D6SRC | |
| Acetic Acid SCHEMBL28643353 | 0.89 | TSHR (0.48) | TSHRLMNAMAPK1CACNA2D1CACNB2 | |
| SCHEMBL6390318 | 0.86 | PTGS2 (0.48) | TSHRALDH1A1CYP2D6 | |
| SCHEMBL29184903 | 0.86 | ESR1 (0.46) | TSHR | |
| SCHEMBL8681266 | 0.81 | TSHR (0.41) | TSHRLMNAMAPK1ALDH1A1HIF1A | |
| SCHEMBL6965069 | 0.81 | SRD5A2 (0.54) | TSHR | |
| SCHEMBL9547891 | 0.78 | TSHR (0.64) | TSHRLMNAMAPK1CACNA2D1CACNB2 | |
| SCHEMBL6962580 | 0.77 | ESR1 (0.62) | TSHRLMNAALDH1A1KDM4EHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4605392-A1 | METHODS FOR TREATING CANCER | Antares Therapeutics, Inc. (US) | 2025-08-27 | — | — | EP | disclosed |
| US-20250027118-A1 | PHENYL ALCOHOLS FROM GAS FERMENTATION | LANZATECH, INC. | 2025-01-23 | — | — | US | disclosed |
| WO-2024086809-A1 | METHODS FOR TREATING CANCER | SCORPION THERAPEUTICS, INC. (US) | 2024-04-25 | — | — | WO | disclosed |
| WO-2023057548-A1 | CCR6 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2023-04-13 | — | — | WO | disclosed |
| US-9873713-B2 | Process for synthesizing highly optically active 1,3-disubstituted allenes | ZHEJIANG UNIVERSITY (CN) | 2018-01-23 | — | — | US | disclosed |
| US-9464033-B2 | Alkynyl phenyl derivative compounds for treating ophthalmic diseases and disorders | ACUCELA INC. (US) | 2016-10-11 | — | — | US | disclosed |
| US-9452153-B2 | Amine derivative compounds for treating ophthalmic diseases and disorders | ACUCELA INC. (US) | 2016-09-27 | — | — | US | disclosed |
| US-20160193181-A1 | AMINE DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. | 2016-07-07 | — | — | US | disclosed |
| US-20160185812-A1 | PROCESS FOR SYNTHESIZING HIGHLY OPTICALLY ACTIVE 1,3-DISUBSTITUTED ALLENES | ZHEJIANG UNIVERSITY (CN) | 2016-06-30 | — | — | US | disclosed |
| US-20160185812-A1 | PROCESS FOR SYNTHESIZING HIGHLY OPTICALLY ACTIVE 1,3-DISUBSTITUTED ALLENES | ZHEJIANG UNIVERSITY (CN) | 2016-06-30 | — | — | US | disclosed |
| US-20100256142-A1 | SYNTHESIS OF FUNCTIONALIZED OCTAHYDRO-ISOQUINOLIN-1-ONE-8- CARBOXAMIDES, OCTAHYDRO-ISOQUINOLIN-1-ONE-8-CARBOXYLIC ESTERS AND ANALOGS, AND THERAPEUTIC METHODS | UNIVERSITY OF NORTH CAROLINA | 2010-10-07 | — | — | US | disclosed |
| US-20100256142-A1 | SYNTHESIS OF FUNCTIONALIZED OCTAHYDRO-ISOQUINOLIN-1-ONE-8- CARBOXAMIDES, OCTAHYDRO-ISOQUINOLIN-1-ONE-8-CARBOXYLIC ESTERS AND ANALOGS, AND THERAPEUTIC METHODS | UNIVERSITY OF NORTH CAROLINA | 2010-10-07 | — | — | US | disclosed |
| US-20100197922-A1 | AZABICYCLOALKANE COMPOUNDS | THERAVANCE, INC. (US) | 2010-08-05 | — | — | US | disclosed |
| US-7732441-B2 | Azabicycloalkane compounds | THERAVANCE, INC. (US) | 2010-06-08 | — | — | US | disclosed |
| US-20100029722-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-02-04 | — | — | US | disclosed |
| US-20090281149-A1 | Amine Derivative Compounds for Treating Ophthalmic Diseases and Disorders | ACUCELA, INC. (US) | 2009-11-12 | — | — | US | disclosed |
| US-20090062353-A1 | Alkynyl phenyl derivative compounds for treating ophthalmic diseases and disorders | ACUCELA, INC. | 2009-03-05 | — | — | US | disclosed |
| US-20080293713-A1 | Inhibitors of Diacylglycerol O-acyltransferase Type 1 Enzyme | ABBOTT LABORATORIES (US) | 2008-11-27 | — | — | US | disclosed |
| US-20080139603-A1 | Azabicycloalkane compounds | THERAVANCE BIOPHARMA R&D IP, LLC | 2008-06-12 | — | — | US | disclosed |
| US-7358244-B2 | Azabicycloalkane compounds | THERAVANCE, INC. (US) | 2008-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139603-A1 | Azabicycloalkane compounds | ADRB1, ADRB2, ADRA2B | TSHR 303/4885LMNA 4154/4885MAPK1 1230/4885 |
| US-20160193181-A1 | AMINE DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | PDE6D, CLN6, AADAT | TSHR 1801/4885LMNA 814/4885MAPK1 3218/4885 |
| US-20080293713-A1 | Inhibitors of Diacylglycerol O-acyltransferase Type 1 Enzyme | DGAT1, DGAT2, LCAT | TSHR 1852/4885LMNA 4304/4885MAPK1 1247/4885 |
| US-20090062353-A1 | Alkynyl phenyl derivative compounds for treating ophthalmic diseases and disorders | PDE6D, STARD3, PDE6C | TSHR 3834/4885LMNA 183/4885MAPK1 2868/4885 |
| US-20100256142-A1 | SYNTHESIS OF FUNCTIONALIZED OCTAHYDRO-ISOQUINOLIN-1-ONE-8- CARBOXAMIDES, OCTAHYDRO-ISOQUINOLIN-1-ONE-8-CARBOXYLIC ESTERS AND ANALOGS, AND THERAPEUTIC METHODS | OPRM1, OPRK1, OPRL1 | TSHR 381/4885LMNA 4488/4885MAPK1 656/4885 |
| US-20100197922-A1 | AZABICYCLOALKANE COMPOUNDS | ADRB1, ADRB2, ADRA2B | TSHR 303/4885LMNA 4154/4885MAPK1 1230/4885 |
| US-20100029722-A1 | ORGANIC COMPOUNDS | SCD, SCD5, FADS2 | TSHR 4191/4885LMNA 2176/4885MAPK1 4752/4885 |
| US-20160185812-A1 | PROCESS FOR SYNTHESIZING HIGHLY OPTICALLY ACTIVE 1,3-DISUBSTITUTED ALLENES | ADH1C, ADH1A, DERA | TSHR 2915/4885LMNA 1817/4885MAPK1 365/4885 |
| US-20090281149-A1 | Amine Derivative Compounds for Treating Ophthalmic Diseases and Disorders | PDE6D, CLN6, AADAT | TSHR 1801/4885LMNA 814/4885MAPK1 3218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.